Barclays
STLN

Barclays’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Barclays’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.6K Sell
15,176
-91,276
-86% -$280K ﹤0.01% 4345
2025
Q4 		$379K Buy
106,452
+20,605
+24% +$76.4K ﹤0.01% 4010
2025
Q3 		$300K Sell
85,847
-17,823
-17% -$61.1K ﹤0.01% 4102
2025
Q2 		$213K Buy
+103,670
New +$259K ﹤0.01% 4233
2023
Q2 		– Sell
-19,840
Closed -$13.4K – 5075
2023
Q1 		$13.4K Buy
19,840
+10,497
+112% +$13.4K ﹤0.01% 4710
2022
Q4 		$15.4K Buy
9,343
+7,868
+533% +$22.1K ﹤0.01% 4861
2022
Q3 		$7K Buy
1,475
+534
+57% +$3.14K ﹤0.01% 4429
2022
Q2 		$5K Buy
+941
New +$6.85K ﹤0.01% 4789

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's STLN Position: Q1 2026 in Review

Barclays reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 86% in Q1 2026, selling an estimated $280K and leaving 15,176 shares worth $46.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4345.

Barclays first reported a position in STLN in Q2 2022 and has held it in 8 quarters since. The position peaked at $379K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Barclays held 15,176 shares of Starling Oncology Institute, Inc. Common Stock worth $46.6K as of Q1 2026.
  • Barclays sold 91,276 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $280K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4345 holding.
  • Barclays first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2022 and has held it in 8 quarters since.
  • Barclays's Starling Oncology Institute, Inc. Common Stock position peaked at $379K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.